Meeting
2024 ASCO Annual Meeting
Validation of PD-L1 as a predictive biomarker of response in operable gastroesophageal adenocarcinoma: A meta-analysis and meta-regression of neoadjuvant chemoimmunotherapy trials.
Authors
Antonella Cammarota
Sarah Cannon Research Institute UK, London, London, United Kingdom
Antonella Cammarota , Sivesh Kathir Kamarajah , Sheraz Markar , Elizabeth Catherine Smyth
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer - Local-Regional Disease
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 4065)
DOI
10.1200/JCO.2024.42.16_suppl.4065
Abstract #
4065
Poster Bd #
45
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Prospective evaluation of pathologic response with neoadjuvant chemo-immunotherapy in metaplastic breast cancer.
First Author: Nour Abuhadra
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A prospective translational study investigating the association of gut microbiome (GM) diversity with pathological complete response (pCR) after neoadjuvant treatment in early stage rectal and esophageal cancers.
First Author: Ronan Andrew Mc Laughlin
Poster
2022 ASCO Annual Meeting
Phase 2 study of trastuzumab deruxtecan in the neoadjuvant treatment for patients with HER2-positive gastric and gastroesophageal junction adenocarcinoma (EPOC2003).
First Author: Daisuke Takahari
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant nivolumab (N) plus cisplatin (C)/pemetrexed (P) or cisplatin /gemcitabine (G) in resectable NSCLC.
First Author: Ralph Zinner